MiNK Therapeutics presented clinical data at ASGCT 2026 demonstrating that their off-the-shelf iNKT cell therapy, agenT-797, induces different immune responses depending on the disease context—activating anti-tumor inflammation in cancer patients and promoting anti-inflammatory effects in ARDS patients. This unique ability comes from the intrinsic biology of iNKT cells without genetic modification, supporting scalable manufacturing from a single donor batch. The therapy showed promising clinical activity, including tumor remission and improved survival in ARDS, with a favorable safety profile. These results support advancing agenT-797 into a Phase 2 trial for acute lung injury, with preliminary data expected in 2026.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Ethereum (ETH) has outperformed Bitcoin (BTC) in Q3, driven by a rally sparked by a softer CPI report and strong on-chain metrics. The recent surge pushed ETH above $1,900, triggering significant liquidations in futures positions. However, ETH now fa...
Solana's number of wallets holding tokenized real-world assets (RWAs) has exceeded 300,000, surpassing Ethereum's roughly 200,000 holders. While Solana's RWA value doubled in 2026 to $3.45 billion, Ethereum still leads with $16.3 billion in tokenized...
Baidu's board has approved a plan to convert to a dual-primary listing on the Hong Kong Stock Exchange's Main Board, alongside its existing Nasdaq listing. This move aims to enhance the liquidity of Baidu's shares, broaden its investor base, and prov...
